Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 8/20 | 0.39 |
| ▸ | EDNRA | P25101 | 4/20 | 0.33 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.32 |
| ▸ | EDNRB | P24530 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16090884 | 0.93 | ERN1 (0.39) | ERN1EDNRATUBB1EDNRBNPC1 | |
| SCHEMBL16727618 | 0.93 | ERN1 (0.40) | ERN1EDNRATUBB1EDNRBNPC1 | |
| SCHEMBL18521911 | 0.87 | EDNRA (0.35) | EDNRAEDNRBNPC1RAB9AHPGD | |
| SCHEMBL10328199 | 0.86 | ERN1 (0.38) | ERN1EDNRATUBB1EDNRB | |
| SCHEMBL14617865 | 0.86 | ERN1 (0.38) | ERN1EDNRATUBB1EDNRB | |
| SCHEMBL2087673 | 0.84 | ERN1 (0.39) | ERN1 | |
| SCHEMBL10177100 | 0.74 | GJB2 (0.33) | NPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL18521910 | 0.74 | GJB2 (0.33) | NPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL146539 | 0.72 | PTGER1 (0.39) | NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL10177098 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163704-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | SLC5A1, SLC5A2, SLC2A1 | ERN1 2914/4885EDNRA 904/4885TUBB1 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.